Cancer and Metastasis Reviews

, Volume 18, Issue 4, pp 427–436

Role of an Anti-epidermal Growth Factor Receptor in Treating Cancer

  • Harlan W. Waksal
Article

Abstract

Recent technological advances, together with the discovery of the important role many growth factors play in modulating cell proliferation and differentiation, have led to the development of novel therapeutic agents for the treatment of cancer. In particular, advances in hybridoma technology and molecular engineering have permitted the development of humanized or chimeric monoclonal antibodies capable of interfering with growth factor signaling pathways. One promising target of interest is the epidermal growth factor receptor (EGFr), which is activated by the ligands EGF and TGF-α. This ligand receptor interaction plays a crucial role in the growth and survival of many human cancers. A chimeric (human/mouse) monoclonal antibody cetuximab (IMC-C225) targets the EGFr and has potential clinical value as an anticancer agent.

EGF receptor monoclonal antibodies cancer chemotherapy radiation therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497, 1975Google Scholar
  2. 2.
    Dillman RO: Antibody therapy. In: Oldham RK (ed) Principles of Cancer Biotherapy, 3rd edn, Kluwer Academic Publishers, The Netherlands, 1998, pp 284–317Google Scholar
  3. 3.
    Aaronson SA: Growth factors and cancer. Science 254: 1146–1153, 1991Google Scholar
  4. 4.
    Di Marco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA, Di Fiore PP: Autocrine interaction between TGFα and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4: 831–838, 1989Google Scholar
  5. 5.
    Rockwell P, Goldstein NI: Role of protein tyrosine kinase receptors in cancer: possibilities for therapeutic intervention. Mol Cell Differ 3: 315–335, 1995Google Scholar
  6. 6.
    Carpenter G: Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56: 881–914, 1987Google Scholar
  7. 7.
    Carpenter G, Cohen S: Epidermal growth factor. J Biol Chem 265: 7709–7712, 1990Google Scholar
  8. 8.
    Derynck R: The physiology of transforming growth factor-α. Adv Cancer Res 58: 27–52, 1992Google Scholar
  9. 9.
    Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183–232, 1995Google Scholar
  10. 10.
    Hendler FJ, Ozanne BW: Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest 74: 647–651, 1984Google Scholar
  11. 11.
    Gullick WJ, Marsden JJ, Whittle N, Ward B, Bobrow L, Waterfield MD: Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res 46: 285–292, 1986Google Scholar
  12. 12.
    Yamamoto T, Kamata N, Kawano H, Shimizu S, Kuroki T, Toyoshima K, Rikimaru K, Nomura N, Ishizaki R, Pastan I, Gamou S, Shimizu N: High incidence of amplification of the epidermal growth factor gene in human squamous carcinoma cell lines. Cancer Res 46: 414–416, 1986Google Scholar
  13. 13.
    Imai Y, Leung CK, Friesen HG, Shiu RP: Epidermal growth factor receptors and effect of epidermal growth factor on receptor growth of human breast cancer cells in long-term tissue culture. Cancer Res 42: 4394–4398, 1982Google Scholar
  14. 14.
    Neal DE, Marsh C, Bennett MK, Abel PD, Hall RR, Sainsbury JR, Harris AL: Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1 (Feb): 366–368, 1985Google Scholar
  15. 15.
    Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H: Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 44: 753–760, 1984Google Scholar
  16. 16.
    Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS, Berger WH: Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res 47: 707–712, 1987Google Scholar
  17. 17.
    Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: 87–98, 1991Google Scholar
  18. 18.
    Sato JD, Kawamoto T, Le AD, Mendelsohn I, Polikoff I, Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1: 511–529, 1983Google Scholar
  19. 19.
    Pellegrini R, Centis F, Martignone S, Mastroianni A, Tagliabue E, Tosi E, Ménard S, Colnaghi MI: Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site. Cancer Immunol Immunother 34: 37–42, 1991Google Scholar
  20. 20.
    Modjtahedi H, Eccles S, Box G, Styles I, Dean C: Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 67: 254–261, 1993Google Scholar
  21. 21.
    Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44: 1002–1007, 1984Google Scholar
  22. 22.
    Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259: 7755–7760, 1984Google Scholar
  23. 23.
    Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, Mendelsohn J: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85: 1327–1333, 1993Google Scholar
  24. 24.
    Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R: Growth regulation of human renal carcinoma cells: role of transforming growth factor α. Cancer Res 52: 3335–3339, 1992Google Scholar
  25. 25.
    Ennis BW, Valverius EM, Bates SE, Lippman ME, Beliot F, Kris R, Schlessinger J, Masui H, Goldenberg A, Mendelsohn J, Dickson RB: Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol 3: 1830–1838, 1989Google Scholar
  26. 26.
    Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95: 1897–1905, 1995Google Scholar
  27. 27.
    Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80: 1605–1611, 1988Google Scholar
  28. 28.
    Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z, Koprowski H: Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res 47: 3692–3696, 1987Google Scholar
  29. 29.
    Fan Z, Baselga J, Masui H, Mendelsohn J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53: 4637–4642, 1993Google Scholar
  30. 30.
    Divgi CR, Welt S, Kris M, Real FX, Yeh SDJ, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM, Mendelsohn J: Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83: 97–104, 1991Google Scholar
  31. 31.
    Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1: 1311–1318, 1995Google Scholar
  32. 32.
    Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151: 1523–1530, 1997Google Scholar
  33. 33.
    Prewett M, Rockwell P, Rose C, Zuklys K, Goldstein NI: Altered cell cycle distribution and cyclin-CDK protein expression in A431 epidermoid carcinoma cells treated with doxorubicin and a chimeric monoclonal antibody to the epidermal growth factor receptor. Mol Cell Differ 4: 167–186, 1996Google Scholar
  34. 34.
    Goldstein NI, Prewett M, Rockwell P, Zalipsky S, Workung P: Treatment of human tumor xenografts with a chimeric monoclonal antibody to the epidermal growth factor receptor in combination with Doxil®, a novel liposomal form of doxorubicin. (Abstract) Presented at Monoclonal Antibodies and Cancer Therapy, New York, Oct 16–18, 1995Google Scholar
  35. 35.
    Prewett M, Rockwell P, Rose C, Goldstein NI: Antitumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin. Int J Oncol 9: 217–224, 1996Google Scholar
  36. 36.
    Goldstein NI, Prewett M, Rockwell P, O'Connor W, Waksal H: The effects of a chimeric antibody to the epidermal growth factor receptor on the growth of prostatic carcinoma xenografts in nude mice. (Abstract) Keystone Conference on Breast and Prostate Cancer, 1996Google Scholar
  37. 37.
    Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, Goldstein NI: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother 19: 419–427, 1996Google Scholar
  38. 38.
    Ye D, Mendelsohn J, Fan Z: Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kipl and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res 5: 2171–2177, 1999Google Scholar
  39. 39.
    Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4: 2957–2966, 1998Google Scholar
  40. 40.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Tortora G: Cooperative inhibition of renal cancer growth by antiepidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. J Natl Cancer Inst 90: 1087–1094, 1998Google Scholar
  41. 41.
    Ye D, Mendelsohn J, Fan Z: Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18: 731–738, 1999Google Scholar
  42. 42.
    Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, DeLaurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G: Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 88: 1770–1776, 1996Google Scholar
  43. 43.
    Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5: 909–916, 1999Google Scholar
  44. 44.
    Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257–265, 1999Google Scholar
  45. 45.
    Kim YB, Perrotte P, Matsumoto T, Tsan R, Dinney CPN, Radinsky R: Immunochemotherapy of human transitional cell carcinoma (TCC) with anti-EGF-R monoclonal antibody (Mab) C225 and the anti-cancer drugs, Taxol® and cisplatinum. American Association for Cancer Research Annual Meeting in New Orleans, LA, March 28–April 1, 1998 (39: 64)Google Scholar
  46. 46.
    Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935–1940, 1999Google Scholar
  47. 47.
    Raben D, Buchsbaum DJ, Gillespie Y, Randall S, Saleh M, Waksal H: Treatment of human intracranial gliomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation. (Abstract) Proc Am Assoc Cancer Res 40: 184, 1999Google Scholar
  48. 48.
    Prewett M, Overholser J, Hooper A, Waksal H, Hicklin DJ: Growth inhibition of human pancreatic carcinoma in vitro and in vivo by chimeric anti-EGF receptor monoclonal antibody C225. (Abstract) Proc Am Assoc Cancer Res 40: 730, 1999Google Scholar
  49. 49.
    Bruns CJ, Portera CA, Tsan R, Hicklin DJ, Radinsky R: Regression of human pancreatic carcinoma growing orthotopically in athymic nude mice by blockade of epidermal growth factor receptor (EGF-R) signaling in combination with gemcitabine. (Abstract) Proc Am Assoc Cancer Res 40: 23, 1999Google Scholar
  50. 50.
    Harris DT, Mastrangelo MJ: Serotherapy of cancer. Semin Oncol 16: 180–198, 1989Google Scholar
  51. 51.
    Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3: 2703–2707, 1997Google Scholar
  52. 52.
    Fan Z, Lu YZ, Wu X, Mendelsohn J: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269: 27595–27602, 1994Google Scholar
  53. 53.
    Bos M, Mendelsohn J, Bowden C, Pfister D, Cooper MR, Cohen R, Burtness B, Andrea GD, Waksal H, Norton L, Baselga J: Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors. (Abstract) American Society of Clinical Oncology Meeting, 1996Google Scholar
  54. 54.
    Falcey J, Pfister D, Cohen R, Cooper M, Bowden C, Burtness B, Mendelsohn J, Waksal H: A study of antiepidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients (pts) with head and neck or lung carcinomas. (Abstract) American Society of Clinical Oncology Meeting, 1997Google Scholar
  55. 55.
    Slovin SF, Kelly WK, Cohen R, Cooper M, Malone T, Weingard K, Waksal H, Falcey J, Mendelsohn J, Scher HI: Epidermal growth factor receptor (EGFr) monoclonal antibody (MoAb) C225 and doxorubicin (DOX) in androgen-independent (AI) prostate cancer (PC): results of a phase Ib/IIa study. (Abstract) American Society of Clinical Oncology Meeting, 1997Google Scholar
  56. 56.
    Cooper MR, Cohen R, Anderson V, Falcey J, Waksal H: Pharmacokinetics of a chimerized monoclonal antibody (225) against the epidermal growth factor receptor (EGFr). (Abstract) American Society of Clinical Oncology Meeting, 1998Google Scholar
  57. 57.
    Perez-Soler R, Shin DM, Donato N, Radinsky R, Khuri F, Glisson BS, Shin H, Matsumoto T, Lawhorn K, Waksal H, Hong WK, Mendelsohn J: Tumor studies in patients with head and neck cancer treated with humanized anti-epidermal growth factor (EGFR) monoclonal antibody C225 in combination with cisplatin. (Abstract) American Society of Clinical Oncology Meeting, 1998Google Scholar
  58. 58.
    Mendelsohn J, Shin DM, Donato N, Khuri F, Radinsky R, Glisson BS, Shin HI, Metz E, Pfister D, Perez-Soler R, Lawhorn K, Matsumoto T, Gunnett K, Falcey J, Waksal H, Hong WK: A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (pts) with recurrent head and neck squamous cell carcinoma (SCC). (Abstract) American Society of Clinical Oncology Meeting, 1999Google Scholar
  59. 59.
    Ezekiel MP, Robert F, Meredith RF, Spencer SA, Newsome I, Khazaeli MD, Peters GE, Saleh M, LoBuglio AF, Waksal HW: Phase I study of anti-epidermal growth factor receptor (EGFR) antibody C225 in combination with irradiation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). (Abstract) American Society of Clinical Oncology Meeting, 1998Google Scholar
  60. 60.
    Ezekiel MP, Bonner JA, Robert F, Meredith RF, Spencer SA, LoBugho AF, Waksal HW: Phase I trial of chimerized anti-epidermal growth factor receptor (anti-EGFr) antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies. (Abstract) American Society of Clinical Oncology Meeting, 1999Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Harlan W. Waksal
    • 1
  1. 1.ImClone Systems IncorporatedNew YorkUSA

Personalised recommendations